GOLGA8R: A Potential Drug Target and Biomarker (G101059918)

Target Name: GOLGA8R

NCBI ID: G101059918

GOLGA8R

Other Name(s): Golgin subfamily A member 8R | golgin subfamily A member 8-like protein 2-like | GOG8R_HUMAN | Golgin A8 family member R | golgin A8 family member R

GOLGA8R: A Potential Drug Target and Biomarker

Golgi8r is a protein that is expressed in most tissues of the body. It is a key component of the endoplasmic reticulum (ER), which is the system for transport and processing of proteins in the cell. GOLGA8R has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

GOLGA8R is a 21-kDa protein that is composed of two main subunits, alpha- and beta-subunits. The alpha-subunit consists of a 126 amino acid residue that is rich in conserved domains, such as a leucine-rich repeat (LRR), a glycine-rich repeat (GGR), and a basic amino acid residue (BAA). The beta-subunit is a 54 amino acid residue that is rich in conserved domains, including a leucine-rich repeat (LRR), a glycine-rich repeat (GGR), and a basic amino acid residue (BAA).

GOLGA8R is expressed in most tissues of the body and is involved in the delivery and processing of proteins to the ER. It is also involved in the regulation of cellular processes, including cell signaling, cell division, and cell survival. GOLGA8R has been shown to play a role in several cellular processes, including the regulation of mitochondrial fusion, the detoxification of xenobiotics, and the regulation of cellular signaling pathways.

As a potential drug target, GOLGA8R has been identified for its role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. GOLGA8R has been shown to be involved in the regulation of several cellular processes that are implicated in the development and progression of these diseases. For example, GOLGA8R has been shown to be involved in the regulation of mitochondrial fusion, which is critical for the growth and survival of cancer cells. It has also been shown to be involved in the regulation of cellular signaling pathways, which are important for the development and progression of neurodegenerative diseases.

In addition to its potential as a drug target, GOLGA8R has also been identified as a potential biomarker for several diseases. GOLGA8R has been shown to be expressed in several types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be expressed in the brains of individuals with neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. In addition, GOLGA8R has been shown to be expressed in the blood of individuals with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

GOLGA8R has also been shown to be involved in several cellular processes that are important for the development and progression of these diseases. For example, GOLGA8R has been shown to be involved in the regulation of the immune response, which is important for the development and progression of autoimmune disorders. It has also been shown to be involved in the regulation of cellular signaling pathways, which are important for the development and progression of neurodegenerative diseases.

In conclusion, GOLGA8R is a protein that is involved in several cellular processes that are important for the development and progression of several diseases. As a potential drug target and biomarker, GOLGA8R has the potential to be a valuable tool for the development of new treatments for these diseases. Further research is needed to fully understand the role of GOLGA8R in these diseases and to develop effective treatments.

Protein Name: Golgin A8 Family Member R

The "GOLGA8R Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLGA8R comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets